JMP’s King Recommends Shares of Pharmacyclics (Audio)

Michael King, an analyst with JMP Group Inc. in New York, says Ibrutinib, a lymphoma drug under development by Pharmacyclics Inc. (PCYC), is “light years ahead” of standard chemotherapy. King talks with Bloomberg’s Tom Keene and Michael McKee on Bloomberg Radio’s "Bloomberg Surveillance."

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.